Abstract
BackgroundProtection of the heart from ischemic damage by rhEPO had been proven in animal myocardial infarction (MI) models. Recent clinical trials testing the effect of rhEPO following PCI have failed to demonstrate either reduction of MI size, or functional improvement. In the US, the time between the onsets of the symptoms and PCI averages about 2 hrs. Legal requirement for informed consent results in further delays of experimental intervention. For instance, in HEBE trial the rhEPO was injected, on average, 3 hrs after successful PCI, in REVEAL trial the time exceeded 4 hrs. We tested the validity of this clinical design in the rat MI model.MethodsIn five groups of 2-month old male Wistar rats, the left descending coronary artery was occluded either by a permanent or by a temporary ligature. After 2 hrs of occlusion, temporary ligatures were released and coronary perfusion was restored. rhEPO (3000U/kg) or saline were injected intraperitoneally either immediately after reperfusion, or 4 hours after reperfusion, or 6 hrs after permanent coronary occlusion. 24 hrs following coronary occlusion rats were euthanized and MI size was measured histologically.ResultsMI size (42 ± 2% of the area at risk in untreated animals) was significantly smaller (19 ± 2% of the area at risk, p<0.0001) in animals treated by rhEPO at the beginning of reperfusion, but was not altered by rhEPO given 4 hrs after beginning of reperfusion or 6 hrs after permanent coronary occlusion.Conclusion BackgroundProtection of the heart from ischemic damage by rhEPO had been proven in animal myocardial infarction (MI) models. Recent clinical trials testing the effect of rhEPO following PCI have failed to demonstrate either reduction of MI size, or functional improvement. In the US, the time between the onsets of the symptoms and PCI averages about 2 hrs. Legal requirement for informed consent results in further delays of experimental intervention. For instance, in HEBE trial the rhEPO was injected, on average, 3 hrs after successful PCI, in REVEAL trial the time exceeded 4 hrs. We tested the validity of this clinical design in the rat MI model. Protection of the heart from ischemic damage by rhEPO had been proven in animal myocardial infarction (MI) models. Recent clinical trials testing the effect of rhEPO following PCI have failed to demonstrate either reduction of MI size, or functional improvement. In the US, the time between the onsets of the symptoms and PCI averages about 2 hrs. Legal requirement for informed consent results in further delays of experimental intervention. For instance, in HEBE trial the rhEPO was injected, on average, 3 hrs after successful PCI, in REVEAL trial the time exceeded 4 hrs. We tested the validity of this clinical design in the rat MI model. MethodsIn five groups of 2-month old male Wistar rats, the left descending coronary artery was occluded either by a permanent or by a temporary ligature. After 2 hrs of occlusion, temporary ligatures were released and coronary perfusion was restored. rhEPO (3000U/kg) or saline were injected intraperitoneally either immediately after reperfusion, or 4 hours after reperfusion, or 6 hrs after permanent coronary occlusion. 24 hrs following coronary occlusion rats were euthanized and MI size was measured histologically. In five groups of 2-month old male Wistar rats, the left descending coronary artery was occluded either by a permanent or by a temporary ligature. After 2 hrs of occlusion, temporary ligatures were released and coronary perfusion was restored. rhEPO (3000U/kg) or saline were injected intraperitoneally either immediately after reperfusion, or 4 hours after reperfusion, or 6 hrs after permanent coronary occlusion. 24 hrs following coronary occlusion rats were euthanized and MI size was measured histologically. ResultsMI size (42 ± 2% of the area at risk in untreated animals) was significantly smaller (19 ± 2% of the area at risk, p<0.0001) in animals treated by rhEPO at the beginning of reperfusion, but was not altered by rhEPO given 4 hrs after beginning of reperfusion or 6 hrs after permanent coronary occlusion. MI size (42 ± 2% of the area at risk in untreated animals) was significantly smaller (19 ± 2% of the area at risk, p<0.0001) in animals treated by rhEPO at the beginning of reperfusion, but was not altered by rhEPO given 4 hrs after beginning of reperfusion or 6 hrs after permanent coronary occlusion. Conclusion
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.